The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy

Trial Profile

The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary)
  • Indications Autoimmune haemolytic anaemia
  • Focus Therapeutic Use
  • Acronyms CAD5
  • Most Recent Events

    • 06 Jan 2017 Status changed from recruiting to completed.
    • 27 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top